N-myristoyltransferase1 and N-myristoyltransferase2 Exhibit Differential Substrate Specificity for HIV-Gag and HIV-Nef

N-myristoyltransferase1 and N-myristoyltransferase2 Exhibit Differential Substrate Specificity for HIV-Gag and HIV-Nef

Bibliographic Details
Main Authors:	Smith Charles, Seaton Kelly
Format:	Article
Language:	English
Published:	BMC 2005-12-01
Series:	Retrovirology

Similar Items

The role of N-myristoyltransferase 1 in tumour development
by: Hong Wang, et al.
Published: (2023-12-01)

QSAR Study of N-Myristoyltransferase Inhibitors of Antimalarial Agents
by: Letícia Santos-Garcia, et al.
Published: (2018-09-01)

Inhibition of N‐myristoyltransferase1 affects dengue virus replication
by: San Suwanmanee, et al.
Published: (2019-09-01)

Inhibitor Trapping in N-Myristoyltransferases as a Mechanism for Drug Potency
by: Danislav S. Spassov, et al.
Published: (2023-07-01)

Novel Hits for N-Myristoyltransferase Inhibition Discovered by Docking-Based Screening
by: Danislav S. Spassov, et al.
Published: (2022-08-01)

N-myristoyltransferase: A potential novel diagnostic marker for colon cancer
by: DeCoteau John, et al.
Published: (2007-11-01)

N-Myristoyltransferases as antileishmanial targets: a piggyback approach with benzoheterocyclic analogues
by: Luis Otávio Junqueira, et al.
Published: (2019-10-01)

N-terminal region of the catalytic domain of human N-myristoyltransferase 1 acts as an inhibitory module.
by: Sujeet Kumar, et al.
Published: (2015-01-01)

The Potential Use of N-Myristoyltransferase as a Biomarker in the Early Diagnosis of Colon Cancer
by: Rajendra K Sharma, et al.
Published: (2011-03-01)

N-Myristoyltransferase, a Potential Antifungal Candidate Drug-Target for Aspergillus flavus
by: Yu Wang, et al.
Published: (2023-02-01)

Exploring Novel N‑Myristoyltransferase Inhibitors: A Molecular Dynamics Simulation Approach
by: Ruqaiya Khalil, et al.
Published: (2019-08-01)

N-myristoyltransferase 2–based Blood Test for the Detection of Colorectal Adenomatous Polyps and Cancer
by: Tharmini Rathinagopal, LNP, MSc, et al.
Published: (2022-03-01)

Genetic validation of Leishmania genes essential for amastigote survival in vivo using N-myristoyltransferase as a model
by: Daniel Paape, et al.
Published: (2020-03-01)

Identification of potent and selective N-myristoyltransferase inhibitors of Plasmodium vivax liver stage hypnozoites and schizonts
by: Diego Rodríguez-Hernández, et al.
Published: (2023-09-01)

Analyzing a potential drug target N-myristoyltransferase of Plasmodium falciparum through in silico approaches
by: Amit Kumar Banerjee, et al.
Published: (2012-01-01)

Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs.
by: Andrew S Bell, et al.
Published: (2012-01-01)

Cellular N-myristoyltransferases play a crucial picornavirus genus-specific role in viral assembly, virion maturation, and infectivity.
by: Irena Corbic Ramljak, et al.
Published: (2018-08-01)

A role of salt bridges in mediating drug potency: A lesson from the N-myristoyltransferase inhibitors
by: Danislav S. Spassov, et al.
Published: (2023-01-01)

QSAR and Pharmacophore Modeling of Nitrogen Heterocycles as Potent Human <i>N</i>-Myristoyltransferase (Hs-NMT) Inhibitors
by: Magdi E. A. Zaki, et al.
Published: (2021-03-01)

A target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodes.
by: Brendan D Galvin, et al.
Published: (2014-09-01)

NMT1 and NMT2 are lysine myristoyltransferases regulating the ARF6 GTPase cycle
by: Tatsiana Kosciuk, et al.
Published: (2020-02-01)

Discovery of Novel Myristic Acid Derivatives as N-Myristoyltransferase Inhibitors: Design, Synthesis, Analysis, Computational Studies and Antifungal Activity
by: Saleem Javid, et al.
Published: (2023-07-01)

In silico identification of microRNAs predicted to regulate N-myristoyltransferase and Methionine Aminopeptidase 2 functions in cancer and infectious diseases.
by: Ranjit Chauhan, et al.
Published: (2018-01-01)

SPI1 Mediates N-Myristoyltransferase 1 to Advance Gastric Cancer Progression via PI3K/AKT/mTOR Pathway
by: Ping Qiu, et al.
Published: (2023-01-01)

Inhibition of vaccinia virus L1 N-myristoylation by the host N-myristoyltransferase inhibitor IMP-1088 generates non-infectious virions defective in cell entry.
by: Lalita Priyamvada, et al.
Published: (2022-10-01)

Association of NMT2 with the acyl-CoA carrier ACBD6 protects the N-myristoyltransferase reaction from palmitoyl-CoA[S]
by: Eric Soupene, et al.
Published: (2016-02-01)

Identification of Potential <i>Leishmania</i> N-Myristoyltransferase Inhibitors from <i>Withania somnifera</i> (L.) Dunal: A Molecular Docking and Molecular Dynamics Investigation
by: Mohamed A. A. Orabi, et al.
Published: (2023-01-01)

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins
by: Brumme, Zabrina L., et al.
Published: (2010)

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.
by: Zabrina L Brumme, et al.
Published: (2009-08-01)

HIV-1 Nef: at the crossroads
by: Garcia J Victor, et al.
Published: (2008-09-01)

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
by: Gloria Omosa-Manyonyi, et al.
Published: (2015-01-01)

P20-18. Diversity of Gag and Nef immunodominant regions in Brazilian HIV-1 B and F1 subtypes
by: Morgado MG, et al.
Published: (2009-10-01)

The recognition of HIV-1 consensus group M Gag and Nef peptide reagents in mono- and multi-clade epidemics: implications for HIV vaccine design
by: Zembe L, et al.
Published: (2012-09-01)

Comparison of HIV-1 nef and gag Variations and Host HLA Characteristics as Determinants of Disease Progression among HIV-1 Vertically Infected Kenyan Children.
by: Matilda Chelimo Saina, et al.
Published: (2015-01-01)

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.
by: Kathryn L Hopkins, et al.
Published: (2014-01-01)

HIV-gag-specific cytotoxic T lymphocytes.
by: Nixon, D, et al.
Published: (1989)

P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses
by: Wagner R, et al.
Published: (2009-10-01)

The Nef activity on HIV-1 infectivity
by: Stéphane eBasmaciogullari, et al.
Published: (2014-05-01)

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.
by: Holly Janes, et al.
Published: (2012-01-01)

N6-methyladenosine of HIV-1 RNA regulates viral infection and HIV-1 Gag protein expression
by: Nagaraja Tirumuru, et al.
Published: (2016-07-01)